R
Richard Labaudinière
Researcher at Pfizer
Publications - 7
Citations - 1716
Richard Labaudinière is an academic researcher from Pfizer. The author has contributed to research in topics: Transthyretin & Tafamidis. The author has an hindex of 6, co-authored 7 publications receiving 1465 citations. Previous affiliations of Richard Labaudinière include Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho,Luis F. Maia,Ana Martins da Silva,Márcia Waddington Cruz,Violaine Planté-Bordeneuve,Pierre Lozeron,Ole B. Suhr,Josep M. Campistol,Isabel Conceição,Hartmut Schmidt,Pedro Trigo,Jeffery W. Kelly,Richard Labaudinière,Jason Chan,Jeff Packman,Amy Wilson,Donna R. Grogan +16 more
TL;DR: This study provides Class II evidence that 20 mg tafamidis QD was associated with no difference in clinical progression in patients with TTR-FAP, as measured by the NIS-LL and the Norfolk QOL-DN score, supporting the hypothesis that preventing TTR dissociation can delay peripheral neurologic impairment.
Journal ArticleDOI
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
Christine Bulawa,Stephen Connelly,Michael Devit,Lan Wang,Charlotte Weigel,James Fleming,Jeff Packman,Evan T. Powers,R. Luke Wiseman,Ted R. Foss,Ian A. Wilson,Jeffery W. Kelly,Richard Labaudinière +12 more
TL;DR: The molecular and structural basis of TTR tetramer stabilization by tafamidis is described, suggesting that binding stabilizes the weaker dimer-dimer interface against dissociation, the rate-limiting step of amyloidogenesis.
Journal ArticleDOI
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Teresa Coelho,Luis F. Maia,Ana Martins da Silva,Márcia Waddington Cruz,Violaine Planté-Bordeneuve,Ole B. Suhr,Isabel Conceição,Hartmut Schmidt,Pedro Trigo,Jeffery W. Kelly,Richard Labaudinière,Jason L. Chan,Jeff Packman,Donna R. Grogan +13 more
TL;DR: Tafamidis was well tolerated, with the reduced rate of neurologic deterioration sustained over 30 months, and slowed neurologic impairment in patients previously given placebo, but treatment benefits were greater when taf amidis was begun earlier.
Journal ArticleDOI
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
Teresa Coelho,Giampaolo Merlini,Christine Bulawa,James Fleming,Daniel P. Judge,Jeffery W. Kelly,Mathew S. Maurer,Violaine Planté-Bordeneuve,Richard Labaudinière,Rajiv Mundayat,Steve Riley,Ilise Lombardo,Pedro E. Huertas +12 more
TL;DR: Tafamidis meglumine is a rationally designed, non-NSAID benzoxazole derivative that binds with high affinity and selectivity to TTR and kinetically stabilizes the tetramer, slowing monomer formation, misfolding, and amyloidogenesis.
Patent
Inhibition of alpha-synuclein toxicity
Susan Lindquist,Tiago F. Outeiro,Richard Labaudinière,James Fleming,Christine E. Bulawa,Charlotte Weigel,Feng Liang,Sandeep K. Gupta,Amy Ripka +8 more
TL;DR: In this paper, compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-nuclein fibrils are a symptom or cause of the disease.